Host-Pathogen Interactions From Measurements of Urinary Cell Free DNA in Kidney Transplantation
肾移植中尿细胞游离 DNA 测量的宿主-病原体相互作用
基本信息
- 批准号:9375180
- 负责人:
- 金额:$ 24.87万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-06-26 至 2019-05-31
- 项目状态:已结题
- 来源:
- 关键词:AllograftingAntibiotic TherapyBacteriaBacterial GenomeBiological AssayCellsClinicalComplicationDNA LibraryDataData SetDevelopmentEnd stage renal failureEvaluationGene ExpressionGenesGenetic FingerprintingsGenomicsGoalsGoldGrowthImmune responseImmunocompromised HostImmunologicsIncidenceInfectionInjuryKidney TransplantationLongevityMeasurementMessenger RNAMetagenomicsMonitorMorbidity - disease rateMulti-Drug ResistanceNatural ImmunityNucleosomesPathogenesisPatientsPilot ProjectsPopulationPreparationRecruitment ActivityRecurrenceRegulator GenesReplication OriginResolutionSamplingSequence AnalysisShotgun SequencingShotgunsSingle-Stranded DNASpecimenStructureStudy SectionSymbiosisTechniquesTestingTimeTissuesTranscription Initiation SiteTransplant RecipientsTransplantationUrinalysisUrinary tract infectionUrineVisitWorkadaptive immunitybasebiobankcell free DNAcell injuryco-infectioncohortdiagnosis standarddifferential expressionmicrobiomemicrobiotamortalitynovelpathogenpromoterresistance mutationresponsetoolurinary
项目摘要
Kidney transplantation is the preferred treatment option for end stage kidney disease, but infectious and
immunological complications limit the lifespan of kidney transplants. Urinary tract infections (UTI) occur at an
alarmingly high rate after kidney transplantation and are associated with urosepsis, allograft loss, and mortality.
The current gold standard for diagnosis of UTI is bacterial culture. Culture-based tests are, however, limited by
their ability to detect only culturable bacteria, do not inform about co-infections and commensal microbiota, do
not inform about bacterial growth dynamics, and do not inform about the host's response to infection.
The goal of this proposal is to invent and apply genomic assays of urinary cell-free DNA that can
simultaneously inform about the composition of the urinary microbiome, growth dynamics of pathogens
associated with UTI, tissue injury in the graft, and the host's immune response to infection. A unique
opportunity for this work is our large cohort of over 250 kidney transplant recipients in which we have serial
biobanked urine specimens as well as routine conventional urine cultures in the first 3 months of transplantation.
Using a newly developed single-stranded DNA library preparation technique, we will profile 290 urinary samples
for cfDNA: i) serial samples from transplant recipients with UTI (prior to, during, and after UTI) ii) serial samples
from recipients with recurrent UTIs; iii) samples from recipients with asymptomatic UTI and negative urinanalysis;
and iv) samples from recipients who do not develop UTI in the first 3 months of transplantation.
We will profile the dynamic urinary microbiome prior to, during, and after UTI in kidney transplantation.
We will investigate whether cfDNA profiles are associated with UTI as well as whether they can anticipate UTI,
UTI recurrence, and multi-drug resistant UTI. Based on the concept that bacterial genome replication rates and
growth dynamics can be estimated from analyses of metagenomic sequence coverage, we will estimate growth
dynamics over time and in response to antibiotic therapy in patients with UTI and recurrent UTI.
We will monitor the host response to UTI via analyses of nucleosome footprints comprised within cfDNA
and via donor specific cfDNA. Our pilot studies indicate that i) the structures of nucleosomal arrays in
transcriptional regulatory elements are preserved and comprised within urinary cfDNA, and ii) that an analysis
of nucleosomal occupancy in gene promoters can be used to quantify gene expression. We will investigate the
differential host's response in subjects who have symptomatic UTI with positive urinalysis and asymptomatic UTI
with negative urinalysis and the differential host's response in UTI patients after antibiotic treatment. We will
assess tissue injury to the allograft in the scope of UTI, using donor specific cfDNA as a marker of allograft injury.
Successful implementation of this proposal will provide a novel understanding of the pathogenesis of UTI as well
as open new avenues for the utilization of cfDNA profiling as a sensitive and noninvasive transplant monitoring
tool.
肾移植是终末期肾病的首选治疗选择,但具有传染性和
免疫并发症限制了肾移植的寿命。尿路感染(UTI)发生在
肾移植后的高发病率令人担忧,并与尿脓毒症、同种异体移植物丢失和死亡率相关。
目前诊断UTI的金标准是细菌培养。然而,基于文化的测试受到以下限制:
他们只检测可培养细菌的能力,不告知合并感染和肠道微生物群,
不告知细菌生长动态,也不告知宿主对感染的反应。
本提案的目标是发明和应用尿游离DNA的基因组测定,
同时告知尿液微生物组的组成,病原体的生长动力学
与UTI、移植物中的组织损伤以及宿主对感染的免疫反应相关。一个独特
这项工作的机会是我们超过250名肾移植受者的大型队列,我们在其中进行了连续的
在移植的前3个月,生物库的尿液样本以及常规的常规尿液培养。
利用新开发的单链DNA文库制备技术,我们将对290份尿液样本进行分析
对于cfDNA:i)来自具有UTI的移植受体的系列样品(在UTI之前、期间和之后)
iii)来自具有无症状UTI和阴性尿分析的接受者的样品;
和iv)来自在移植的前3个月内未发生UTI的受体的样品。
我们将分析肾移植中UTI之前、期间和之后的动态尿液微生物组。
我们将研究cfDNA谱是否与UTI相关以及它们是否可以预测UTI,
UTI复发和多药耐药UTI。基于细菌基因组复制速率和
生长动力学可以从宏基因组序列覆盖率的分析中估计,我们将估计生长
在UTI和复发性UTI患者中随时间推移的动力学和对抗生素治疗的反应。
我们将通过分析cfDNA中包含的核小体足迹来监测宿主对UTI的反应。
以及通过供体特异性cfDNA。我们的初步研究表明,i)核小体阵列的结构,
转录调控元件被保存并包含在尿cfDNA内,和ii)分析
基因启动子中核小体占有率的测定可用于定量基因表达。我们将调查
尿分析阳性的症状性UTI受试者和无症状性UTI受试者的不同宿主应答
尿路感染患者抗生素治疗后尿常规阴性和不同的宿主反应。我们将
使用供体特异性cfDNA作为同种异体移植物损伤的标志物,在UTI范围内评估同种异体移植物的组织损伤。
这一建议的成功实施将提供一个新的理解尿路感染的发病机制以及
作为利用cfDNA谱分析作为敏感和非侵入性移植监测的新途径,
工具.
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(1)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Iwijn De Vlaminck其他文献
Iwijn De Vlaminck的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Iwijn De Vlaminck', 18)}}的其他基金
Cell-free DNA as a versatile analyte for the monitoring of sepsis
游离 DNA 作为监测脓毒症的多功能分析物
- 批准号:
10665402 - 财政年份:2023
- 资助金额:
$ 24.87万 - 项目类别:
A spatially resolved molecular atlas of acute viral myocarditis at single-cell resolution
单细胞分辨率的急性病毒性心肌炎的空间解析分子图谱
- 批准号:
10681925 - 财政年份:2023
- 资助金额:
$ 24.87万 - 项目类别:
Cell-Free DNA in Peritoneal Fluid as a Novel and Versatile Analyte for Monitoring Peritonitis
腹膜液中的游离 DNA 作为监测腹膜炎的新型多功能分析物
- 批准号:
10428638 - 财政年份:2021
- 资助金额:
$ 24.87万 - 项目类别:
Cell-Free DNA in Peritoneal Fluid as a Novel and Versatile Analyte for Monitoring Peritonitis
腹膜液中的游离 DNA 作为监测腹膜炎的新型多功能分析物
- 批准号:
10288893 - 财政年份:2021
- 资助金额:
$ 24.87万 - 项目类别:
Epigenetic Profiling of circulating cell-free DNA for the Monitoring of Graft-Versus-Host Disease after Hematopoietic Cell Transplantation
循环游离 DNA 表观遗传分析用于监测造血细胞移植后移植物抗宿主病
- 批准号:
10328516 - 财政年份:2020
- 资助金额:
$ 24.87万 - 项目类别:
Epigenetic Profiling of circulating cell-free DNA for the Monitoring of Graft-Versus-Host Disease after Hematopoietic Cell Transplantation
循环游离 DNA 表观遗传分析用于监测造血细胞移植后移植物抗宿主病
- 批准号:
10533829 - 财政年份:2020
- 资助金额:
$ 24.87万 - 项目类别:
Epigenetic Profiling of circulating cell-free DNA for the Monitoring of Graft-Versus-Host Disease after Hematopoietic Cell Transplantation
循环游离 DNA 表观遗传分析用于监测造血细胞移植后移植物抗宿主病
- 批准号:
10084808 - 财政年份:2020
- 资助金额:
$ 24.87万 - 项目类别:
Droplet-Assisted RNA targeting by single-cell sequencing to dissect the single-cell heterogeneity of RNA virus infection
通过单细胞测序进行液滴辅助 RNA 靶向分析 RNA 病毒感染的单细胞异质性
- 批准号:
9888327 - 财政年份:2019
- 资助金额:
$ 24.87万 - 项目类别:
Precision monitoring of kidney transplants via single-cell and single-molecule sequencing
通过单细胞和单分子测序精确监测肾移植
- 批准号:
9350514 - 财政年份:2017
- 资助金额:
$ 24.87万 - 项目类别:
Mitochondrial Cell-Free DNA as a Marker of Rejection and Damage-Associated Molecular Pattern in Organ Transplantation
线粒体游离 DNA 作为器官移植中排斥和损伤相关分子模式的标记
- 批准号:
9335715 - 财政年份:2016
- 资助金额:
$ 24.87万 - 项目类别:
相似海外基金
SBIR Phase II: Development of a urine dipstick test that can guide immediate and appropriate antibiotic therapy for treatment of complicated urinary tract infections
SBIR II 期:开发尿液试纸测试,可以指导复杂尿路感染的立即和适当的抗生素治疗
- 批准号:
2213034 - 财政年份:2023
- 资助金额:
$ 24.87万 - 项目类别:
Cooperative Agreement
Personalized Antibiotic Therapy in the Emergency Department: PANTHER Trial
急诊科的个性化抗生素治疗:PANTHER 试验
- 批准号:
10645528 - 财政年份:2023
- 资助金额:
$ 24.87万 - 项目类别:
Strategies for improving the efficacy of combinatorial antibiotic therapy in chronic infections
提高慢性感染联合抗生素治疗疗效的策略
- 批准号:
10736285 - 财政年份:2023
- 资助金额:
$ 24.87万 - 项目类别:
A Novel Bone Targeted Antibiotic Therapy for the Treatment of Infected Fractures
一种治疗感染性骨折的新型骨靶向抗生素疗法
- 批准号:
10603486 - 财政年份:2023
- 资助金额:
$ 24.87万 - 项目类别:
Severe Cutaneous Adverse Reactions Following Outpatient Antibiotic Therapy: A Population-based Study
门诊抗生素治疗后的严重皮肤不良反应:一项基于人群的研究
- 批准号:
449379 - 财政年份:2020
- 资助金额:
$ 24.87万 - 项目类别:
Studentship Programs
Sex-Specific Differences in End-of-Life Burdensome Interventions and Antibiotic Therapy in Nursing Home Residents With Advanced Dementia
患有晚期痴呆症的疗养院居民的临终干预和抗生素治疗的性别差异
- 批准号:
422034 - 财政年份:2020
- 资助金额:
$ 24.87万 - 项目类别:
Optimizing outpatient parenteral antibiotic therapy to support hospital-in-the-home program across the unique environmental conditions of Australia
优化门诊肠外抗生素治疗,以支持澳大利亚独特环境条件下的家庭医院计划
- 批准号:
nhmrc : 1197866 - 财政年份:2020
- 资助金额:
$ 24.87万 - 项目类别:
Investigator Grants
Resistance evolution in the presence of combination antibiotic therapy
联合抗生素治疗下耐药性的演变
- 批准号:
2241853 - 财政年份:2019
- 资助金额:
$ 24.87万 - 项目类别:
Studentship
Host-pathogen interactions in antibiotic therapy for listeriosis
李斯特菌病抗生素治疗中宿主与病原体的相互作用
- 批准号:
18K07106 - 财政年份:2018
- 资助金额:
$ 24.87万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Multipurpose targeted nano-antibiotic therapy to fight tough infection in bones
多用途靶向纳米抗生素疗法可对抗骨骼中的严重感染
- 批准号:
9788269 - 财政年份:2018
- 资助金额:
$ 24.87万 - 项目类别: